Literature DB >> 10098752

The association between CD2+ peripheral blood lymphocyte subsets and the relapse of bladder cancer in prophylactically BCG-treated patients.

E Reyes1, J Carballido, L Manzano, L Moltó, C Olivier, M Alvarez-Mon.   

Abstract

We investigated the potential existence of differences in the distribution of T-lymphocyte subsets and in the proliferative response of these CD2+ cells to polyclonal mitogens in patients with transitional cell bladder carcinoma (SBTCC) treated with prophylactic intracavitary instillations of bacillus Calmette-Guerin (BCG) according to their clinical response to this treatment. Before BCG treatment, different subset distribution (CD8+ and CD3+ CD56+), activation antigen expression (CD3+ HLA- DR+) and proliferative response to mitogenic signals were found in CD2+ cells from SBTCC patients prophylactically treated with BCG who remained free of disease or those who had recurrence of tumour. Otherwise, the prophylactic intracavitary BCG instillations in SBTCC patients are associated with a transitory variation of T-lymphocyte subset distribution (CD4 and CD8) and activation antigens expression (CD25).

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10098752      PMCID: PMC2362230          DOI: 10.1038/sj.bjc.6690185

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  31 in total

Review 1.  [Immunotherapy of urothelial neoplasms. Experimental and clinical implications of alpha interferon].

Authors:  J Carballido; M Alvarez-Mon; C Olivier; L Moltó
Journal:  Arch Esp Urol       Date:  1990       Impact factor: 0.436

2.  Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall.

Authors:  S Prescott; K James; T B Hargreave; G D Chisholm; J F Smyth
Journal:  J Urol       Date:  1992-06       Impact factor: 7.450

3.  Comparison of augmentation of human natural killer cell cytotoxicity by interferon-alpha subtypes.

Authors:  A Verhagen; I R Mackay; M Rowley; M Tymms
Journal:  Nat Immun Cell Growth Regul       Date:  1990

4.  T-cell subsets required for intravesical BCG immunotherapy for bladder cancer.

Authors:  T L Ratliff; J K Ritchey; J J Yuan; G L Andriole; W J Catalona
Journal:  J Urol       Date:  1993-09       Impact factor: 7.450

5.  Quantification of proliferative and suppressive responses of human T lymphocytes following ConA stimulation.

Authors:  M Niks; M Otto; B Busová; J Stefanovic
Journal:  J Immunol Methods       Date:  1990-02-09       Impact factor: 2.303

6.  Differential expression of homing-associated adhesion molecules by T cell subsets in man.

Authors:  L J Picker; L W Terstappen; L S Rott; P R Streeter; H Stein; E C Butcher
Journal:  J Immunol       Date:  1990-11-15       Impact factor: 5.422

7.  Reduced LAK cytotoxicity of peripheral blood mononuclear cells in patients with bladder cancer: decreased LAK cytotoxicity caused by a low incidence of CD56+ and CD57+ mononuclear blood cells.

Authors:  G G Hermann; K R Petersen; K Steven; J Zeuthen
Journal:  J Clin Immunol       Date:  1990-11       Impact factor: 8.317

Review 8.  Current recommendations for the management of bladder cancer. Drug therapy.

Authors:  J A Witjes
Journal:  Drugs       Date:  1997-03       Impact factor: 9.546

Review 9.  Mechanisms of action of bacillus Calmette-Guérin in the treatment of superficial bladder cancer.

Authors:  J J Patard; D K Chopin; L Boccon-Gibod
Journal:  World J Urol       Date:  1993       Impact factor: 4.226

10.  Two distinct factors are required for induction of T-cell growth.

Authors:  E L Larsson; N N Iscove; A Coutinho
Journal:  Nature       Date:  1980-02-14       Impact factor: 49.962

View more
  1 in total

1.  Relationship between response to interferon-alpha and function of peripheral blood mononuclear cells in chronic hepatitis C patients.

Authors:  Fatima Esquivel; Agustín Albillos; Flavio Carrión; Alfredo Prieto; Eduardo Reyes; Belén Martínez-Martin; José Luis Calleja; Guillermo Cacho; Melchor Alvarez-Mon
Journal:  Dig Dis Sci       Date:  2002-10       Impact factor: 3.199

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.